Cargando…
FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
The life-long inhibitor risk in non-severe hemophilia A has been an important clinical and research focus in recent years. Non-severe hemophilia A is most commonly caused by point mutation, missense F8 genotypes, of which over 500 variants are described. The immunogenic potential of just a single am...
Autor principal: | Hart, Daniel P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399083/ https://www.ncbi.nlm.nih.gov/pubmed/32849511 http://dx.doi.org/10.3389/fimmu.2020.01498 |
Ejemplares similares
-
Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
por: Cai, Yuanhua, et al.
Publicado: (2020) -
Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity
por: Pandey, Gouri Shankar, et al.
Publicado: (2013) -
Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018) -
The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A
por: Kim, Ju Young, et al.
Publicado: (2019) -
Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)